Pacira Pharmaceuticals
David Schwalb is the Director of Analytical Development for Cell and Gene Therapies at Pacira BioSciences, Inc., since May 2021, where responsibilities include the development and execution of analytical strategies for the PCRX-201 HCAd gene therapy program and managing both external and internal analytical assay development. Previously, David served as Associate Director of Analytical Development at Pacira, leading the technical transfer of the Flexion CGT program and overseeing investigations and audits. Prior experience includes roles as Sr Scientist II at Voyager Therapeutics, managing the analytical development and process analytics team, and Scientist II and Scientist roles at bluebird bio and Alexion Pharmaceuticals, focusing on analytical development of gene therapy products and protein therapeutics. David started a career as a Scientific Associate at NitroMed after earning an MS in Biochemistry from UMass Chan Medical School and a BS in Biology/Communications from Worcester Polytechnic Institute.
This person is not in any teams
This person is not in any offices
Pacira Pharmaceuticals
4 followers
Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology.